Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328238 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAMAPTTHRBALDH1A1 | |
| SCHEMBL12352613 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAMAPTALDH1A1LMNA | |
| SCHEMBL854061 | 0.85 | ALDH1A1 (0.55) | SMN1; SMN2GAAMAPTALDH1A1LMNA | |
| SCHEMBL852833 | 0.84 | ALDH1A1 (0.61) | SMN1; SMN2GAAMAPTTHRBALDH1A1 | |
| SCHEMBL31727050 | 0.84 | ALDH1A1 (0.61) | SMN1; SMN2GAAMAPTTHRBALDH1A1 | |
| SCHEMBL16305345 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2GAAMAPTALDH1A1LMNA | |
| SCHEMBL10126786 | 0.82 | KMT2A (0.50) | SMN1; SMN2GAAMAPTTHRBALDH1A1 | |
| SCHEMBL2061743 | 0.82 | ALDH1A1 (0.66) | SMN1; SMN2MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL29769093 | 0.82 | ALDH1A1 (0.66) | SMN1; SMN2MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL17543872 | 0.82 | FFAR4 (0.55) | SMN1; SMN2GAAMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | BEONE MEDICINES I GMBH (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024246838-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2024-12-05 | — | — | WO | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | SMN1; SMN2 4467/4885GAA 3821/4885MAPT 3116/4885 |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4592/4885GAA 1958/4885MAPT 3554/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | SMN1; SMN2 4467/4885GAA 3821/4885MAPT 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.